Sort   by:  
 Page size 
UnknownSafety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Not available
S-EPMC5657013 | biostudies-literature
UnknownQuality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Not available
S-EPMC6804841 | biostudies-literature
Genomicsrenal cell carcinoma
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Homo sapiens 
2015-06-19 | E-GEOD-66885 | biostudies-arrayexpress
GenomicsGenome-wide maps of H3K36me3 in metastatic renal cell carcinoma and isogenic renal cell carcinoma cell lines
We report the application of H3K36me3 ChIP sequencing in SETD2 genotyped samples Examination of H3K36me3 in SETD2 wild-type, mutant renal cell carcinoma and SETD2 isogenic cell lines
ORGANISM(S): Homo sapiens 
2015-06-19 | E-GEOD-66884 | biostudies-arrayexpress
UnknownAMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Not available
S-EPMC4666535 | biostudies-literature
UnknownPBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Not available
S-EPMC7195420 | biostudies-literature
UnknownHigh-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Not available
S-EPMC4679725 | biostudies-literature
UnknownA Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
Not available
S-EPMC10014037 | biostudies-literature
UnknownA phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.
Not available
S-EPMC12141888 | biostudies-literature
UnknownA Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.
Not available
S-EPMC11406637 | biostudies-literature
Sort   by:  
 Page size